

Table 4(a): PBS processing (excl. Drs Bag) years ending: Jun 2011 to end Jun 2014 - Section 85 Only

Year	Subsidised Prescription Volume	Under co-payment Prescription Volume	Government Cost \$
Year Ending Jun 11	187,804,540	n.a.	7,323,148,803
Year Ending Jun 12	194,548,705	n.a.	7,528,204,119
Year Ending Jun 13	196,953,259	62,019,475	7,069,490,924
Year Ending Jun 14	209,452,240	72,322,451	7,292,550,961
<i>Change</i>	12,498,981	10,302,976	223,060,037
<i>%</i>	6.35	16.61	3.16

Table 4(b): PBS processing - PBS subsidised and under co-payment prescriptions (incl. Drs Bag) year ending: Jun 2014 - Section 85 Only

	Year Ending Jun 13	Year Ending Jun 14	Change	%
Highest volume drug: Atorvastatin				
Subsidised Prescription Volume	9,611,688	8,912,377	-699,311	-7.28
UCP Prescription Volume	176,266	1,362,258	1,185,992	672.84
Government Cost (\$)	422,780,054	279,187,250	-143,592,804	-33.96
Highest Govt cost drug: Rosuvastatin				
Subsidised Prescription Volume	7,485,726	7,806,237	320,511	4.28
UCP Prescription Volume	225,307	550,748	325,441	144.44
Government Cost (\$)	302,362,304	287,914,893	-14,447,411	-4.78
Highest volume ATC Level 2: LIPID MODIFYING AGENTS				
Subsidised Prescription Volume	25,043,985	24,978,107	-65,878	-0.26
UCP Prescription Volume	1,331,068	2,887,307	1,556,239	116.92
Government Cost (\$)	1,028,654,443	872,648,621	-156,005,822	-15.17
Highest Government cost ATC Level 2: LIPID MODIFYING AGENTS				
Subsidised Prescription Volume	25,043,985	24,978,107	-65,878	-0.26
UCP Prescription Volume	1,331,068	2,887,307	1,556,239	116.92
Government Cost (\$)	1,028,654,443	872,648,621	-156,005,822	-15.17
Greatest increase in Govt. cost ATC Level 2: IMMUNOSUPPRESSANTS				
Subsidised Prescription Volume	708,796	820,097	111,301	15.70
UCP Prescription Volume	7,941	9,808	1,867	23.51
Government Cost (\$)	597,465,701	743,663,075	146,197,374	24.47